Joseph Treat

3.7k total citations
102 papers, 2.5k citations indexed

About

Joseph Treat is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Joseph Treat has authored 102 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 69 papers in Pulmonary and Respiratory Medicine and 19 papers in Molecular Biology. Recurrent topics in Joseph Treat's work include Lung Cancer Treatments and Mutations (64 papers), Lung Cancer Research Studies (46 papers) and Lung Cancer Diagnosis and Treatment (32 papers). Joseph Treat is often cited by papers focused on Lung Cancer Treatments and Mutations (64 papers), Lung Cancer Research Studies (46 papers) and Lung Cancer Diagnosis and Treatment (32 papers). Joseph Treat collaborates with scholars based in United States, Germany and France. Joseph Treat's co-authors include Coleman K. Obasaju, A Rahman, Larry R. Kaiser, Ruqin Chen, Paul V. Woolley, David Waterhouse, Deborah Forst, Joan H. Schiller, Shaker R. Dakhil and Martin Marciniak and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Joseph Treat

97 papers receiving 2.4k citations

Peers

Countries citing papers authored by Joseph Treat

Since Specialization

Citations

This map shows the geographic impact of Joseph Treat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Treat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Treat more than expected).

Fields of papers citing papers by Joseph Treat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Treat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Treat. The network helps show where Joseph Treat may publish in the future.

Co-authorship network of co-authors of Joseph Treat

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Treat. A scholar is included among the top collaborators of Joseph Treat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Treat. Joseph Treat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors 2025 ·Clinical Lung Cancer ·J. Nicholas Bodor, Jonathan E. Dowell, Joseph Treat, Janakiraman Subramanian, (unknown), Eric Lee, Kamalesh K. Sankhala, (unknown), Go Makimoto, Eisaku Miyauchi, Kartik Konduri, Hajime Asahina, Shuji Murakami, Yueh‐Feng Wen, Yung‐Hung Luo, Sung‐Joon Chang, Reginald B. Ewesuedo, Jianli Zhou, (unknown)	1
2	P2.12-07 Phase II Trial of LP-300 + Pemetrexed/Carboplatin in Patients Who Never Smoked with Lung Adenocarcinoma After TKI Progression 2023 ·Journal of Thoracic Oncology ·Joseph Treat, (unknown), Bruce Bank, (unknown), Kartik Konduri, Nashat Gabrail, Reginald B. Ewesuedo, Kishor Bhatia, J. Nicholas Bodor, Yasushi Goto	1
3	Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing 2023 ·International Journal of Molecular Sciences ·Sandra V. Fernandez, (unknown), Shilpa Rao, (unknown), Fathima Sheriff, Hossein Borghaei, Efrat Dotan, (unknown), Martin J. Edelman, Joseph Treat, Julia Judd, R. Katherine Alpaugh, Y. Lynn Wang, Jian Yu, Mariusz A. Wasik, Don A. Baldwin	2
4	Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non–Small-Cell Lung Cancer 2016 ·Clinical Lung Cancer ·Edward B. Garon, Martin Reck, Luis Paz‐Ares, Santiago Ponce, Jesús Corral Jaime, Óscar Juan, Ernest Nadal, Pablo Lee, Rita P. Dalal, Jingyi Liu, (unknown), Joseph Treat, Kazuhiko Nakagawa	9
5	Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non–Small-Cell Lung Cancer 2015 ·Clinical Lung Cancer ·Thomas E. Stinchcombe, Hossein Borghaei, Scott Barker, Joseph Treat, Coleman K. Obasaju	19
6	Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S. 2015 ·Lung Cancer ·(unknown), Beth Woods, Lisa M. Hess, Joseph Treat, Mark E. Boye, Peter Bryden, Katherine B. Winfree	17
7	PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer 2014 ·Journal of Thoracic Oncology ·Ralph Zinner, Coleman K. Obasaju, David R. Spigel, Robert Weaver, J. Thaddeus Beck, David Waterhouse, Manuel Modiano, Borys Hrinczenko, Petros Nikolinakos, Jingyi Liu, Andrew Koustenis, Katherine B. Winfree, Symantha Melemed, Susan C. Guba, Waldo Ortuzar, D. Desaiah, Joseph Treat, Ramaswamy Govindan, Helen J. Ross	120
8	Pemetrexed Use in the Adjuvant Setting for Completely Resectable Non–Small-Cell Lung Cancer 2013 ·Clinical Lung Cancer ·George R. Simon, Christian Manegold, Scott Barker, Joseph Treat, Carla Visseren‐Grul, Coleman K. Obasaju	4
9	Toxicity and Response of Pemetrexed Plus Carboplatin or Cisplatin with Concurrent Chest Radiation Therapy for Patients with Locally Advanced Non-small Cell Lung Cancer: A Phase I Trial 2010 ·Journal of Thoracic Oncology ·J.H. Heinzerling, Hak Choy, Randall Hughes, Ramaswamy Govindan, Jeffrey D. Bradley, Lee S. Schwartzberg, Guangbin Peng, Joseph Treat, (unknown), Coleman K. Obasaju	7
10	A Comparison of White and African American Outcomes from a Three-Arm, Randomized, Phase III Multicenter Trial of Advanced or Metastatic Non-small Cell Lung Cancer 2010 ·Journal of Thoracic Oncology ·Coleman K. Obasaju, Rafat Ansari, Mark A. Socinski, Ruqin Chen, Matthew Monberg, Robert B. Catalano, Donna M. Marinucci, Darla Liles, (unknown), Robert L. Comis, Joseph Treat	7
11	Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States 2008 ·Lung Cancer ·Kathleen Lang, Martin Marciniak, D Faries, Michael E. Stokes, Don P. Buesching, Craig C. Earle, Joseph Treat, (unknown), David R. Thompson	50
12	P1-229: The impact of shortened vitamin supplementation lead-in time before pemetrexed (P) in patients with relapsed small-cell lung cancer (SCLC) 2007 ·Journal of Thoracic Oncology ·Mark A. Socinski, Robert N. Raju, Donald Richards, (unknown), Craig H. Reynolds, Ruqin Chen, Jane Bromund, Joseph Treat, Coleman K. Obasaju	1
13	Phase I Study of Radical Thoracic Radiation, Weekly Irinotecan, and Cisplatin in Locally Advanced Non-small Cell Lung Carcinoma 2007 ·Journal of Thoracic Oncology ·Corey J. Langer, Robert A. Somer, Samuel Litwin, Steven J. Feigenberg, Benjamin Movsas, (unknown), Eric J. Sherman, Michael Millenson, (unknown), Chao Huang, Joseph Treat	7
14	Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non–small cell lung carcinoma: long-term results and associations with pathologic response 2004 ·Journal of Thoracic and Cardiovascular Surgery ·Mitchell Machtay, Jason H. Lee, James Stevenson, Joseph B. Shrager, Kenneth M. Algazy, Joseph Treat, Larry R. Kaiser	45
15	A phase I trial of 96-hour padlitaxel infusion plus accelerated radiotherapy of unrespectable head and neck cancer 1999 ·International Journal of Radiation OncologyBiologyPhysics ·Mitchell Machtay, (unknown), Morton M. Kligerman, Joseph Treat, G S Weinstein, Randal S. Weber, Natasha Mirza, Ara A. Chalian, David I. Rosenthal	11
16	Plasma thrombospondin levels in patients with gynecologic malignancies 1994 ·Cancer ·Faith E. Nathan, Enrique Hernández, Charles J. Dunton, Joseph Treat, Hanna I. Switalska, Rosaline R. Joseph, George P. Tuszynski	51
17	Continuous Infusion 5-Fluorouracil with Bolus Adriamycin and Mitomycin and Low-Dose Cisplatin (FAMP) in the Treatment of Metastatic Gastric Carcinoma: An Evaluation of Efficacy and Toxicity 1991 ·Cancer Investigation ·James Raschko, Elizabeth A. Johnson, Winston Ueno, Paul V. Woolley, Joseph Treat	4
18	Transfusion-induced graft-versus-host disease in patients with malignant lymphoma a case report and review of the literature 1990 ·Cancer ·Thomas R. Spitzer, Ronan A. Cahill, Michele Cottler‐Fox, Joseph Treat, Ronald A. Sacher, H. Joachim Deeg	22
19	LACK OF COMMON HAPLOTYPE AMONG FOUR FAMILY MEMBERS WITH LATE‐ONSET KAPOSI'S SARCOMA 1989 ·International Journal of Immunogenetics ·John R. Neefe, Joseph Treat, (unknown), Philip S. Schein, A. Holly Johnson	2
20	Peripheral Neuropathy and Low Dose Cisplatin 1988 ·American Journal of Clinical Oncology ·Andrew Greenspan, Joseph Treat	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact